199 related articles for article (PubMed ID: 35223548)
1. Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives.
Henrique IM; Sacerdoti F; Ferreira RL; Henrique C; Amaral MM; Piazza RMF; Luz D
Front Cell Infect Microbiol; 2022; 12():825856. PubMed ID: 35223548
[TBL] [Abstract][Full Text] [Related]
2. Role of Recent Therapeutic Applications and the Infection Strategies of Shiga Toxin-Producing
Hwang SB; Chelliah R; Kang JE; Rubab M; Banan-MwineDaliri E; Elahi F; Oh DH
Front Cell Infect Microbiol; 2021; 11():614963. PubMed ID: 34268129
[TBL] [Abstract][Full Text] [Related]
3. Gb3-Coated Bovine Milk Exosomes as a Practical Neutralizer for Shiga Toxin.
Lu M; Zhu Y; Li D; Zhou Z; Lin H; Hong H; Shi J; Wu Z
ACS Appl Bio Mater; 2023 Dec; 6(12):5798-5808. PubMed ID: 37988327
[TBL] [Abstract][Full Text] [Related]
4. Shiga Toxin (Stx) Classification, Structure, and Function.
Melton-Celsa AR
Microbiol Spectr; 2014 Aug; 2(4):EHEC-0024-2013. PubMed ID: 25530917
[TBL] [Abstract][Full Text] [Related]
5. Shiga Toxins: An Update on Host Factors and Biomedical Applications.
Liu Y; Tian S; Thaker H; Dong M
Toxins (Basel); 2021 Mar; 13(3):. PubMed ID: 33803852
[TBL] [Abstract][Full Text] [Related]
6. Shiga toxin (Stx) type 2-induced increase in O-linked N-acetyl glucosamine protein modification: a new therapeutic target?
Bova RA; Melton-Celsa A
EMBO Mol Med; 2022 Jan; 14(1):e15389. PubMed ID: 34935281
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of O-GlcNAcylation protects from Shiga toxin-mediated cell injury and lethality in host.
Lee KS; Lee J; Lee P; Jeon BC; Song MY; Kwak S; Lee J; Kim JS; Kim DJ; Kim JH; Tesh VL; Lee MS; Park SK
EMBO Mol Med; 2022 Jan; 14(1):e14678. PubMed ID: 34842355
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2.
Jeong KI; Chapman-Bonofiglio S; Singh P; Lee J; Tzipori S; Sheoran AS
BMC Immunol; 2010 Mar; 11():16. PubMed ID: 20334660
[TBL] [Abstract][Full Text] [Related]
9. Protection against Shiga Toxins.
Kavaliauskiene S; Dyve Lingelem AB; Skotland T; Sandvig K
Toxins (Basel); 2017 Feb; 9(2):. PubMed ID: 28165371
[TBL] [Abstract][Full Text] [Related]
10. Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.
Tzipori S; Sheoran A; Akiyoshi D; Donohue-Rolfe A; Trachtman H
Clin Microbiol Rev; 2004 Oct; 17(4):926-41, table of contents. PubMed ID: 15489355
[TBL] [Abstract][Full Text] [Related]
11. New Monoclonal Antibodies against a Novel Subtype of Shiga Toxin 1 Produced by Enterobacter cloacae and Their Use in Analysis of Human Serum.
Skinner C; Patfield S; Khalil R; Kong Q; He X
mSphere; 2016; 1(1):. PubMed ID: 27303707
[TBL] [Abstract][Full Text] [Related]
12. Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects
Luz D; Amaral MM; Sacerdoti F; Bernal AM; Quintilio W; Moro AM; Palermo MS; Ibarra C; Piazza RMF
Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30513821
[TBL] [Abstract][Full Text] [Related]
13. Degradation and inactivation of Shiga toxins by nitrogen gas plasma.
Sakudo A; Imanishi Y
AMB Express; 2017 Dec; 7(1):77. PubMed ID: 28389899
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells.
Akiyoshi DE; Rich CM; O'Sullivan-Murphy S; Richard L; Dilo J; Donohue-Rolfe A; Sheoran AS; Chapman-Bonofiglio S; Tzipori S
Infect Immun; 2005 Jul; 73(7):4054-61. PubMed ID: 15972493
[TBL] [Abstract][Full Text] [Related]
15. The ether lipid precursor hexadecylglycerol protects against Shiga toxins.
Bergan J; Skotland T; Lingelem AB; Simm R; Spilsberg B; Lindbäck T; Sylvänne T; Simolin H; Ekroos K; Sandvig K
Cell Mol Life Sci; 2014 Nov; 71(21):4285-300. PubMed ID: 24740796
[TBL] [Abstract][Full Text] [Related]
16. Shiga toxin type 2 B subunit protects mice against toxin challenge when leashed and bundled by a stable pentameric coiled-coil molecule.
Tamaki Y; Harakuni T; Arakawa T
Vaccine; 2024 Mar; 42(7):1757-1767. PubMed ID: 38365487
[TBL] [Abstract][Full Text] [Related]
17. Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature.
Bauwens A; Betz J; Meisen I; Kemper B; Karch H; Müthing J
Cell Mol Life Sci; 2013 Feb; 70(3):425-57. PubMed ID: 22766973
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of biologically active Shiga toxins in cell-free systems.
Ramm F; Kaser D; König I; Fellendorf J; Wenzel D; Zemella A; Papatheodorou P; Barth H; Schmidt H
Sci Rep; 2024 Mar; 14(1):6043. PubMed ID: 38472311
[TBL] [Abstract][Full Text] [Related]
19. The crystal structure of shiga toxin type 2 with bound disaccharide guides the design of a heterobifunctional toxin inhibitor.
Jacobson JM; Yin J; Kitov PI; Mulvey G; Griener TP; James MN; Armstrong G; Bundle DR
J Biol Chem; 2014 Jan; 289(2):885-94. PubMed ID: 24225957
[TBL] [Abstract][Full Text] [Related]
20. A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy.
Kirkland ME; Patfield S; Hughes AC; Hernlem B; He X
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0059823. PubMed ID: 38047751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
